This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Winners & Losers: Teva

Health stocks reflected varied news on the Monday after the July Fourth holiday, from unfavorable trial results, side effects and cost-effectiveness assessments as well analyst notes.

Teva (TEVA - Get Report) skidded after the company said that according to top-line results of a trial dubbed "FORTE" the higher, 40mg dose of Copaxone was no more effective than the already FDA-approved 20mg dose in relapsing-remitting multiple sclerosis (RRMS).

Teva shares fell $4.54, or 9.6%, to $42.66. The stock is a component of the Amex pharmaceutical index, which was down 5.74, or 1.9%, at 293.79.

Incidentally, the only stock component of the pharmaceutical index that wasn't in the red Monday afternoon was pharma player Wyeth (WYE). Its shares were up 52 cents, or 1.1%, at $47.51. The company said in a release on July 3 (the last regular trading day prior to Monday) that it received European approval to market Relistor subcutaneous injection for pain-killer-induced constipation in patients with advanced illness who are receiving palliative care when typical laxative therapy is insufficient.

One stock bucking downward trends, APP Pharmaceuticals (APPX) rocketed $5.27, or 30%, to $23.09 after German health care company Frenenius said it will buy the Schaumburg, Ill., drugmaker for $3.7 billion, or roughly $23 a share, a 29% premium to APP's closing price on Thursday.

Meanwhile, a medical expert panel that advises European regulators preliminarily concluded that GlaxoSmithKline's (GSK - Get Report) Tyverb is not a cost-effective treatment for breast cancer. The drug, which has received conditional approval in Europe, has to receive full government approval in order to be available to all patients at subsidized rates. Glaxo shares were down $1.01, or 2.2%, at $45.76.

Also on the decline, Genentech (DNA) gave up $2.43, or 3.1%, to $75.51 on unconfirmed cases of PML, a deadly brain infection, in rheumatoid arthritis patients treated with Rituxan, as mentioned in a Leerink Swann report. PML is listed on the drug's label as a possible side effect.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
GSK $47.02 0.00%
KND $24.33 0.00%
MRK $57.75 0.00%
TEVA $61.98 0.00%
AAPL $123.25 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs